Equities analysts expect that Evolent Health will post ($0.41) earnings per share for the current year. They set an outperform rating and a $30.00 price objective on the stock. Leerink Swann also issued estimates for Evolent Health's Q4 2017 earnings at ($0.05) EPS, FY2017 earnings at ($0.53) EPS and FY2018 earnings at $0.10 EPS.
More interesting news about Evolent Health Inc (NYSE:EVH) were released by: Bizjournals.com and their article: "Evolent Health CEO: "We probably saw more of a pullback than we would've expected" published on August 09, 2017 as well as Prnewswire.com's news article titled: "Evolent Health Announces Second Quarter 2017 Results" with publication date: August 07, 2017. The technology company reported ($0.13) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.13). The business had revenue of $107.30 million during the quarter, compared to the consensus estimate of $104.45 million. During the same period in the previous year, the firm earned ($0.20) earnings per share.
ILLEGAL ACTIVITY WARNING: "Evolent Health, Inc (EVH) Downgraded by ValuEngine" was first reported by Stock Observer and is owned by of Stock Observer. If you are accessing this article on another website, it was stolen and republished in violation of U.S. and global trademark & copyright legislation. The original version of this story can be read at https://transcriptdaily.com/2017/08/12/oppenheimer-holdings-analysts-decrease-earnings-estimates-for-evolent-health-inc-nyseevh.html. Jefferies Group LLC restated a "buy" rating and set a $28.00 price objective on shares of Evolent Health in a research report on Thursday, April 13th. Robert W. Baird restated an "outperform" rating and set a $35.00 price objective (up from $30.00) on shares of Evolent Health in a research report on Wednesday, June 14th.
Among 11 analysts covering Evolent Health (NYSE:EVH), 11 have Buy rating, 0 Sell and 0 Hold. Finally, TheStreet upgraded Evolent Health from a "d" rating to a "c-" rating in a research report on Monday, May 22nd. According to buy-side analysts, moving averages work quite well in strong trending conditions, but often poorly in choppy or ranging conditions.EVH has analyst rating of 1.40 on scale of 1-5. The company now has a consensus rating of "Buy" and a consensus target price of $29.90.
North Korean missiles and the challenges they pose to the United States
The same system is now set up in Guam, a US territory in the South Pacific that has emerged as a potential target for Kim. The country has threatened nuclear attacks against the USA and its allies as well as a missile strike on Guam.
In recent trade, Evolent Health, Inc. The 50 day moving average moved down $-7.14 whereas the 200 day average was down by -21.51%. The firm has "Outperform" rating by FBR Capital given on Friday, August 5. Stock's twelve month price oscillated between $27.50 and $14.50. The stock was sold at an average price of $25.87, for a total value of $110,706,137.75.
Earnings per share (EPS) is the portion of a company's profit allocated to each outstanding share of common stock. Also, CFO Nicholas Mcgrane sold 1,667 shares of the firm's stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $23.51, for a total transaction of $128,764.27.
Steve Wigginton, CEO, Valence Health disclosed the sale of 959 shares of EVH stock. Insiders sold a total of 10,153,967 shares of company stock valued at $253,648,377 in the last three months. TimesSquare Capital Management LLC boosted its stake in shares of Evolent Health by 15.0% in the second quarter. Bank of Montreal Can now owns 6,220 shares of the technology company's stock worth $138,000 after buying an additional 6,077 shares in the last quarter. Point72 Asia Hong Kong Ltd purchased a new position in Evolent Health during the first quarter worth $126,000. FMR LLC now owns 9,864,775 shares of the technology company's stock worth $250,073,000 after buying an additional 5,333,252 shares in the last quarter. Dimensional Fund Advisors LP bought a new position in shares of Evolent Health during the second quarter valued at approximately $2,912,000. FMR LLC increased its position in shares of Evolent Health by 117.7% in the second quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in Evolent Health by 286.7% in the first quarter. Gradient Investments LLC now owns 16,719 shares of the technology company's stock worth $424,000 after buying an additional 489 shares during the period.
Now we will discuss the financial strength of Evolent Health, Inc.